Plavix
Product Images NDC 16590-288

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Plavix (NDC 16590-288). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chart Image (Plavix 75mg Chart)

This is a graph displaying the cumulative event rate in percentage for either faial or non-faial vascular events over a period of 36 months of follow-up. The graph compares the use of aspirin versus Plavix. The data points for each medication are given at the 12, 18, 24, 30, and 36-month follow-up intervals.*

FDA Label Image

Chart Image 2 (Plavix 75mg Chart2)

This is a graphical representation of the cumulative event rate (%) of Cardiovascular Death, Myocardial Infarction, and Stroke in patients who were given Placebo (+ aspirin) and Plavix (+ aspirin) over a follow-up period of up to 12 months. The graph shows that the Plavix treatment is more effective than placebo in reducing the incidence of these events. Other standard therapies as appropriate were also used.*

FDA Label Image

Chart Image3 (Plavix 75mg Chart3)

This appears to be a report on the results of a study comparing a placebo to clopidogrel (a medication used to reduce the risk of heart attack and stroke) in terms of reducing the risk of death. There were 1845 deaths (8.1%) in the placebo group and 1726 deaths (75%) in the clopidogrel group. The study found a 7% proportional risk reduction (p = 0.03) associated with clopidogrel. The number of days since randomization was also recorded.*

FDA Label Image

Label Image (Plavix 75mg Label)

This is a medication description. The tablets contain 97.875mg of Clopidogrel bisulfate equivalent to 75mg Clopidogrel base. The manufacturer is Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. The tablets have an NDC code of 63653-11715 and a lot number of 9651527. They should be discarded after 05/12/2020. The remaining text is not legible. Possible side effects include diarrhea and stomach pains.*

FDA Label Image

Structure Image (Plavix 75mg Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.